Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis

Journal of Lipid Research

Volumn 52, Issue 8, 2011, Pages 1561-1568

  Ge, Xuemei ^a   Yin, Liya ^a   Ma, Huiyan ^a   Li, Tiangang ^a   Chiang, John Y L ^a   Zhang, Yanqiao ^a  

^a Northeastern Ohio Medical University   (United States)

Author keywords

AKR1B7; Cholesterol; Farnesoid X receptor; Triglyceride

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; CHOLESTEROL; FARNESOID X RECEPTOR; MALONALDEHYDE; TRIACYLGLYCEROL;

AKR1B7 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DETOXIFICATION; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE; GENE CONTROL; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; IN VIVO STUDY; INTESTINE; LIPID METABOLISM; LIPID PEROXIDATION; LIPOLYSIS; LIVER; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; WILD TYPE;

ADENOVIRIDAE; ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION; GENETIC VECTORS; GLUCONEOGENESIS; HOMEOSTASIS; HUMANS; LIVER; MALONDIALDEHYDE; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSFECTION; TRIGLYCERIDES;

EID: 79960687149     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M015859     Document Type: Article

References (33)

1. Farmer, E. E., and C. Davoine. 2007. Reactive electrophile species. Curr. Opin. Plant Biol. 10: 380-386.
2. Lau, E. T., D. Cao, C. Lin, S. K. Chung, and S. S. Chung. 1995. Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor-regulated protein in the adrenal gland. Biochem. J. 312: 609-615.
3. Lefrancois-Martinez, A. M., C. Tournaire, A. Martinez, M. Berger, S. Daoudal, D. Tritsch, G. Veyssiere, and C. Jean. 1999. Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. J. Biol. Chem. 274: 32875-32880.
4. Schneider, C., N. A. Porter, and A. R. Brash. 2008. Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. J. Biol. Chem. 283: 15539-15543.
5. Zhang, Y., and P. A. Edwards. 2008. FXR signaling in metabolic disease. FEBS Lett. 582: 10-18.
6. Mencarelli, A., B. Renga, E. Distrutti, and S. Fiorucci. 2009. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296: H272-H281.
7. -/- mice. J. Lipid Res. 50: 1090-1100.
8. Flatt, B., R. Martin, T. L. Wang, P. Mahaney, B. Murphy, X. H. Gu, P. Foster, J. Li, P. Pircher, M. Petrowski, et al. 2009. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52: 904-907.
9. Zhang, S., J. Wang, Q. Liu, and D. C. Harnish. 2009. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fi- brosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51: 380-388.
10. Fiorucci, S., G. Rizzo, E. Antonelli, B. Renga, A. Mencarelli, L. Riccardi, S. Orlandi, M. Pruzanski, A. Morelli, and R. Pellicciari. 2005. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314: 584-595.
11. Inagaki, T., A. Moschetta, Y. K. Lee, L. Peng, G. Zhao, M. Downes, R. T. Yu, J. M. Shelton, J. A. Richardson, J. J. Repa, et al. 2006. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. USA. 103: 3920-3925.
12. Yang, F., X. Huang, T. Yi, Y. Yen, D. D. Moore, and W. Huang. 2007. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67: 863-867.
13. Maran, R. R., A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, F. J. Gonzalez, et al. 2009. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 328: 469-477.
14. Kim, I., K. Morimura, Y. Shah, Q. Yang, J. M. Ward, and F. J. Gonzalez. 2007. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 28: 940-946.
15. Huang, W., K. Ma, J. Zhang, M. Qatanani, J. Cuvillier, J. Liu, B. Dong, X. Huang, and D. D. Moore. 2006. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 312: 233-236.
16. Schmidt, D. R., S. Schmidt, S. R. Holmstrom, M. Makishima, R. T. Yu, C. L. Cummins, D. J. Mangelsdorf, and S. A. Kliewer. 2011. AKR1B7 is induced by the farnesoid X receptor and metabolizes bile acids. J. Biol. Chem. 286: 2425-2432.
17. Zhang, Y., L. Yin, J. Anderson, H. Ma, F. J. Gonzalez, T. M. Willson, and P. A. Edwards. 2010. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J. Biol. Chem. 285: 3035-3043.
18. Yin, L., H. Ma, X. Ge, P. A. Edwards, and Y. Zhang. 2011. Hepatic hepatocyte nuclear factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 31: 328-336.
19. Zhang, Y., F. Y. Lee, G. Barrera, H. Lee, C. Vales, F. J. Gonzalez, T. M. Willson, and P. A. Edwards. 2006. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA. 103: 1006-1011.
20. Lee, H., Y. Zhang, F. Y. Lee, S. F. Nelson, F. J. Gonzalez, and P. A. Edwards. 2006. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J. Lipid Res. 47: 201-214.
21. Zhang, Y., H. R. Kast-Woelbern, and P. A. Edwards. 2003. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278: 104-110.
22. Liu, M. J., Y. Takahashi, T. Wada, J. He, J. Gao, Y. Tian, S. Li, and W. Xie. 2009. The aldo-keto reductase Akr1b7 gene is a common transcriptional target of xenobiotic receptors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 76: 604-611.
23. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
24. Lu, T. T., M. Makishima, J. J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, and D. J. Mangelsdorf. 2000. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell. 6: 507-515.
25. Hassan, A. S., M. T. Subbiah, and P. Thiebert. 1980. Specific changes of bile acid metabolism in spontaneously diabetic Wistar rats. Proc. Soc. Exp. Biol. Med. 164: 449-452.
26. Nervi, F. O., C. H. Severin, and V. D. Valdivieso. 1978. Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochim. Biophys. Acta. 529: 212-223.
27. Uchida, K., S. Makino, and T. Akiyoshi. 1985. Altered bile acid metabolism in nonobese, spontaneously diabetic (NOD) mice. Diabetes. 34: 79-83. (Pubitemid 15192856)
28. Andersen, E., G. Karlaganis, and J. Sjovall. 1988. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur. J. Clin. Invest. 18: 166-172.
29. Matsukuma, K. E., M. K. Bennett, J. Huang, L. Wang, G. Gil, and T. F. Osborne. 2006. Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J. Lipid Res. 47: 2754-2761.
30. Yoon, J. C., P. Puigserver, G. Chen, J. Donovan, Z. Wu, J. Rhee, G. Adelmant, J. Stafford, C. R. Kahn, D. K. Granner, et al. 2001. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 413: 131-138. (Pubitemid 32867868)
31. Ma, K., P. K. Saha, L. Chan, and D. D. Moore. 2006. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116: 1102-1109.
32. Volle, D. H., J. J. Repa, A. Mazur, C. L. Cummins, P. Val, J. Henry-Berger, F. Caira, G. Veyssiere, D. J. Mangelsdorf, and J. M. Lobaccaro. 2004. Regulation of the aldo-keto reductase gene akr1b7 by the nuclear oxysterol receptor LXRalpha (liver X receptor- alpha) in the mouse intestine: putative role of LXRs in lipid detoxification processes. Mol. Endocrinol. 18: 888-898.
33. Baumann, C., B. Davies, M. Peters, U. Kaufmann-Reiche, M. Lessl, and F. Theuring. 2007. AKR1B7 (mouse vas deferens protein) is dispensable for mouse development and reproductive success. Reproduction. 134: 97-109. (Pubitemid 47244842)